The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis shows that revenues are projected to increase from $15.5 billion in 2010 to $19.2 in 2017 at a CAGR of 3.1%. Prescription and OTC contraceptives held an 82% and 18% market share, respectively, in 2010. The intrauterine devices market was valued at $1,370.4m in 2010 and revenues are projected to increase to $1,398.1m in 2017, at a CAGR of 0.3%. However, revenues are expected to decline in 2015 due to the patent expiry of Mirena and the availability of low cost hormonal intrauterine devices. Strategic consolidations through acquisition accounted for 31% of M&A deals.
- The report analyzes the market characterization, pipeline analysis and key M&A trends for oral, topical and injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market.
- Data and analysis on the contraceptives market in leading geographies: the US, the UK, Germany, France, Italy, Spain and Japan.
- Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2002–2010, with forecasts to 2017.
- Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and annual cost of usage.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the contraceptives market, which includes companies such as Bayer, Johnson & Johnson, Reckitt Benckiser, Church & Dwight and Merc
Copyright©2010 PR Newswire.
All rights reserved